46
47
18.
Riis J., Simmons J. P., Goodwin G. P.
Preferences for enhancement phar-
maceuticals: The reluctance to enhance fundamental traits // Journal of Con-
sumer Research. 2008. Vol. 35. № 3. P. 495−508.
19.
Schelle K. J. et al.
Attitudes toward pharmacological cognitive enhance-
ment: a review // Frontiers in systems neuroscience. 2014. Vol. 8. Art. 53.
P. 1−14.
20.
Schermer M.
Enhancements, easy shortcuts, and the richness of human
activities // Bioethics. 2008. Vol. 22. № 7. P. 355−363.
21.
Scheske C., Schnall S.
The ethics of “smart drugs”: Moral judgments
about healthy people’s use of cognitive-enhancing drugs // Basic and Applied
Social Psychology. 2012. Vol. 34. № 6. P. 508−515.
22.
Schicktanz S., Schweda M., Wynne B.
The ethics of ‘public understand-
ing of ethics’: why and how bioethics expertise should include public and
patients’ voices // Medicine, health care and philosophy. 2012. Vol. 15. № 2.
P. 129−139.
23.
Schwartz C.
Generation Adderall // The New York Times Maga-
zine. 12.10.2016. [Электронный ресурс]. URL: https://www.nytimes.
com/2016/10/16/magazine/generation-adderall-addiction (дата обращения:
10.11.2017).
24.
Schwarz A.
ADHD Nation: Children, Doctors, Big Pharma, and the
Making of an American Epidemic. New York: Simon and Schuster, 2016. 352 p.
25.
Yesavage J. A. et al.
Donepezil and flight simulator performance: effects
on retention of complex skills // Neurology. 2002. Vol. 59. № 1. P. 123−125.
Достарыңызбен бөлісу: